Analyst Sean Laaman of Morgan Stanley maintained a Hold rating on Neurocrine, retaining the price target of $185.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sean Laaman has given his Hold rating due to a combination of factors related to the outlook for VYKAT XR and how it compares with market expectations. He highlights that Soleno’s internal forecasts for VYKAT XR’s peak sales, profit margins, and revenue durability are meaningfully below current Street assumptions, suggesting that consensus may be overestimating the long‑term revenue opportunity embedded in Neurocrine’s shares.
At the same time, the internal projections assume very strong cost discipline and unusually high peak EBIT margins, which Laaman views as aggressive relative to benchmarks from similar commercial‑stage biotech peers. Together, these more conservative revenue expectations and arguably optimistic margin assumptions point to a less compelling risk‑reward profile at current valuation, leading him to maintain a neutral, or Hold, stance on Neurocrine pending further management disclosure and validation of the VYKAT XR trajectory.
According to TipRanks, Laaman is a 5-star analyst with an average return of 14.4% and a 64.66% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Neurocrine, Exelixis, and Halozyme.
In another report released on April 6, BMO Capital also assigned a Hold rating to the stock with a $140.00 price target.